Operator

Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2026 Earnings Conference Call. [Operator Instructions]

I will now turn the conference over to Paul Goodson, Head of Investor Relations. You may begin.

Paul Goodson
Head of Investor Relations

Thank you, operator. Earlier today, Cytek Biosciences released financial results for the first quarter ended March 31, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an e-mail to investors@cytekbio.com. A copy of the news release is also available on the Investor Relations section of Cytek's website at investors.cytekbio.com.

Please note that, we will be referencing a slide presentation during the call today that has been posted to the Investors section of our corporate website.

Joining me today from Cytek are Wenbin Jiang, CEO; and Bill McCombe, CFO.

As a reminder, on Slide 2, we will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities and financial projections. These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated in these statements.

Additional information regarding these risks and uncertainties appears in our slide presentation in the section entitled Forward-Looking Statements in the